Analysis of two COVID-19 melanoma patients treated with targeted therapy (BRAF and MEK inhibitors) in convalescent stage demonstrated a phenotypic profile that was similar to nonmelanoma COVID-19 patients (fig. This evidence concerns the gene MAP2K7 and melanoma.